T_NN
cell_NN
reactivity_NN
to_TO
Sjogren_NN
's_POS
syndrome_NN
related_JJ
antigen_NN
La_NN
-LRB-_-LRB-
SSB_NN
-RRB-_-RRB-
._.

OBJECTIVE_NN
._.

Many_JJ
patients_NNS
with_IN
primary_JJ
Sjogren_NN
's_POS
syndrome_NN
-LRB-_-LRB-
SS_NN
-RRB-_-RRB-
make_VBP
high_JJ
titer_NN
IgG_NN
autoantibodies_NNS
to_TO
the_DT
La_NN
-LRB-_-LRB-
SSB_NN
-RRB-_-RRB-
antigen_NN
,_,
suggesting_VBG
antigen_NN
specific_JJ
T_NN
cell-B_NN
cell_NN
interactions_NNS
._.

T_NN
cell_NN
responses_NNS
to_TO
some_DT
nuclear_JJ
antigens_NNS
,_,
particularly_RB
U1RNP_NN
,_,
have_VBP
been_VBN
detected_VBN
in_IN
patients_NNS
with_IN
systemic_JJ
lupus_NN
erythematosus_NN
-LRB-_-LRB-
SLE_NN
-RRB-_-RRB-
and_CC
in_IN
healthy_JJ
subjects_NNS
._.

We_PRP
investigated_VBD
T_NN
cell_NN
reactivity_NN
to_TO
the_DT
autoantigen_NN
SSB_NN
in_IN
patients_NNS
with_IN
SS_NN
and_CC
healthy_JJ
controls_NNS
._.

METHODS_NNS
._.

Using_VBG
the_DT
-LCB-_-LRB-
3H-RCB-thymidine_NN
proliferation_NN
assay_NN
,_,
we_PRP
determined_VBD
reactivity_NN
to_TO
purified_VBN
recombinant_JJ
SSB_NN
-LRB-_-LRB-
rSSB_NN
-RRB-_-RRB-
in_IN
20_CD
patients_NNS
with_IN
SS_NN
and_CC
19_CD
controls_NNS
._.

Specificity_NN
was_VBD
determined_VBN
using_VBG
tetanus_NN
toxoid_NN
,_,
endotoxin_NN
,_,
and_CC
3_CD
other_JJ
autoantigens_NNS
-LRB-_-LRB-
PBC_NNP
._.
M2_NNP
,_,
Sc170_NN
,_,
and_CC
GAD_NN
-RRB-_-RRB-
._.

Precursor_NN
frequency_NN
was_VBD
calculated_VBN
by_IN
limiting_VBG
dilution_NN
analysis_NN
._.

HLA_NN
Class_NN
II_CD
dependency_NN
was_VBD
investigated_VBN
using_VBG
anti-Class_JJ
II_CD
monoclonal_JJ
antibodies_NNS
._.

HLA-DR_NN
typing_NN
was_VBD
by_IN
polymerase_NN
chain_NN
reaction_NN
and_CC
sequence_NN
specific_JJ
oligonucleotide_NN
typing_NN
._.

RESULTS_NNS
._.

Six_CD
of_IN
20_CD
patients_NNS
with_IN
SS_NN
and_CC
10\/19_CD
controls_NNS
proliferated_VBD
to_TO
La_NN
-LRB-_-LRB-
rSSB_NN
-RRB-_-RRB-
._.

Precursor_NN
frequency_NN
of_IN
anti-SSB_JJ
T_NN
cells_NNS
was_VBD
1:77,040_CD
and_CC
1:115,000_JJ
in_IN
2_CD
healthy_JJ
subjects_NNS
and_CC
1:230,250_CD
and_CC
1:103,034_CD
in_IN
two_CD
patients_NNS
with_IN
SS_NN
._.

Anti-HLA-DR_NN
abrogated_VBD
proliferation_NN
to_TO
SSB_NN
and_CC
tetanus_NN
toxoid_NN
._.

Thirteen_CD
of_IN
15_CD
patients_NNS
with_IN
SS_NN
and_CC
4\/17_CD
controls_NNS
were_VBD
HLA-DR3_NN
positive_JJ
,_,
with_IN
no_DT
apparent_JJ
association_NN
of_IN
HLA-DR3_NN
with_IN
SSB_NN
reactivity_NN
in_IN
controls_NNS
._.

CONCLUSION_NN
._.

Anti-La_NN
-LRB-_-LRB-
SSB_NN
-RRB-_-RRB-
specific_JJ
T_NN
cells_NNS
occur_VBP
in_IN
a_DT
significant_JJ
proportion_NN
of_IN
controls_NNS
and_CC
in_IN
some_DT
patients_NNS
with_IN
SS_NN
._.

The_DT
function_NN
of_IN
SSB_NN
T_NN
cells_NNS
in_IN
controls_NNS
remains_VBZ
to_TO
be_VB
defined_VBN
._.

They_PRP
may_MD
represent_VB
immunoregulatory_JJ
cells_NNS
,_,
and_CC
further_JJ
analysis_NN
of_IN
these_DT
cells_NNS
,_,
and_CC
a_DT
comparison_NN
to_TO
those_DT
found_VBN
in_IN
patients_NNS
with_IN
SS_NN
,_,
may_MD
elucidate_VB
normal_JJ
immunoregulation_NN
and_CC
the_DT
derangements_NNS
that_WDT
lead_VBP
to_TO
Sjogren_NN
's_POS
syndrome_NN
._.

